肺炎球菌7价结合疫苗(Pfizer Inc.)(Pneumococcal 7-valent conjugate vaccine(Pfizer Inc.)) - 在研适应症：肺炎球菌感染，侵袭性肺炎链球菌感染，中耳炎_专利_临床

概要

基本信息

药物类型

预防性疫苗、多价疫苗、结合疫苗

别名

Pneumococcal 7-valent CRM197 vaccine conjugate、Pneumococcal conjugate vaccine, 7 valent、pneumococcal polysaccharide serotype 4/pneumococcal polysaccharide serotype 6B/pneumococcal polysaccharide serotype 9V/pneumococcal polysaccharide serotype 14/ pneumococcal oligosaccharide serotype 18C/pneumococcal polysaccharide serotype 19F/pneumococcal polysaccharide serotype 23F

+ [8]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Wyeth Pharmaceuticals LLC

Pfizer Inc.

非在研机构

Pfizer Ltd.Wyeth AB

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2000-02-17),

侵袭性肺炎链球菌感染中耳炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

50

项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的临床试验

NCT01307449

/ CompletedN/AIIT

Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)

Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vaccine development particularly for the geriatric population.
In this trial, the investigators will study the immunologic differences of two FDA approved licensed pneumococcal vaccines between a younger and an older group. Twenty two healthy volunteers between the age of 25-40 and sixty six healthy volunteers between the ages of 60-89 will be enrolled in the study. Each participant in the study will be given one pneumococcal shot. Blood work will be obtained prior to vaccination, one day, three days, seven days, fourteen days, as well as one month and six months after vaccination. Throughout the duration of the study, the participants will be monitored for safety.

开始日期2014-04-01

申办/合作机构

Emory University

[+1]

NCT02133469

/ CompletedN/AIIT

Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children.

A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype S. pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F combined) in 2 to 5 years old healthy Chinese children.

开始日期2012-06-01

申办/合作机构

北京市卫生局

[+1]

JPRN-UMIN000008025

/ CompletedN/AIIT

Safety Research of administration of DTP, PCV7, Hib Vaccines to Infants at NICU - Safety Research of administration of DTP, PCV7, Hib Vaccines to Infants at NICU

开始日期2012-05-01

申办/合作机构-

100 项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的临床结果

登录后查看更多信息

100 项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的转化医学

登录后查看更多信息

100 项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的专利（医药）

登录后查看更多信息

2,300

项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of a 20-valent pneumococcal conjugate vaccine for pneumococcal disease prevention in the Slovak pediatric population

Article

作者: Nassar, Thea Paoula ; Šebo, Peter ; Hroncova, Dagmar ; Wannaadisai, Warisa ; Kuchta, Lubos

BACKGROUND:

Slovakia has introduced pneumococcal conjugate vaccines (PCVs) in the national immunization program (NIP) since 2011. Recently licensed for use in the pediatric population in Europe, the 20-valent pneumococcal conjugate vaccine (PCV20) is poised to become a new potential standard of care (SoC) in the pediatric national immunization program (NIP). Therefore, this study aims to assess the cost-effectiveness and the clinical and economic outcomes of the PCV20 compared to PCV13 and PCV15 in Slovakian infants.

METHODS:

A decision-analytic Markov model was employed to estimate the cost-effectiveness of implementing PCV20 versus two lower-valent PCVs in Slovakian infants aged over 10 years. Health outcomes comprised cases of pneumococcal disease, life years, and quality-adjusted life years (QALY). Economic outcomes included vaccination- and disease-associated costs. Outcomes were evaluated for the entire population to capture full vaccine benefits (indirect effects). Epidemiological inputs were sourced from local surveillance reports or published literature. Direct and indirect vaccine effects (VE) were estimated from vaccine impact, effectiveness, and clinical studies of PCV7 and PCV13. Economic inputs were informed by local studies and 2024 Slovak national reimbursement cost. Comprehensive deterministic sensitivity analysis and scenario analyses were examined. The study assumed a willingness-to-pay threshold (WTP) of €40,377/QALY.

RESULTS:

Over 10 years, PCV20 3 + 1 was predicted to prevent over 810 invasive pneumococcal disease (IPD) cases, 885,000 pneumonia cases, 6,600 otitis media (OM) cases, and 16,600 disease-associated deaths compared with PCV13 2 + 1. The disease prevention subsequently resulted in €326.7 million direct medical costs savings, 96,430,859 additional QALYs gain and an ICER of €1,349/QALY. Comparable trends were observed versus PCV15 2 + 1, with PCV20 preventing more pneumococcal disease cases, providing greater additional QALYs, and being cost-effective under the prespecified threshold. Results were consistent across base case and scenario analyses.

CONCLUSIONS:

Implementing PCV20 into the Slovakian pediatric NIP is projected to yield the most significant clinical and economic benefits compared to the two lower-valent PCVs, due to its more extensive protection against a broader range of pneumococcal serotypes. Despite an additional cost of dose and visit, PCV20 was estimated to be cost-effective at the Slovak WTP threshold versus other SoC options over a 10-year time horizon.

2026-12-31·Human Vaccines & Immunotherapeutics

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial

Article

作者: Ponce, Philip ; Giriappa, Balachandra ; Anderson, Annaliesa ; Su, Xin ; Lei, Lanyu ; McElwee, Kathleen ; Pai, Seema ; Watson, Wendy ; Choraria, Nirmalkumar ; Portka, Miranda ; Drozd, Jelena ; Bickham, Kara

Streptococcus pneumoniae is a leading cause of bacteremia, bacterial meningitis, and pneumonia. In India, there is an unmet need for an expanded valent pneumococcal conjugate vaccine (PCV) to protect older adults. This phase 3, single-arm study evaluated the safety and immunogenicity of 20-valent PCV (PCV20) in adults ≥18 y of age in India. Participants were enrolled into two age groups (18‒49 and ≥50 y old) and received a single dose of PCV20. Immunogenicity endpoints included geometric mean fold rises (GMFRs) in pneumococcal serotype-specific opsonophagocytic activity (OPA) titers from before to 1 month after vaccination. Safety endpoints included percentages of participants reporting local reactions and systemic events within 7 d after vaccination and adverse events (AEs) and serious AEs within 1 month after vaccination. All 400 participants (200 in each age group) received a single dose of PCV20. OPA geometric mean titers substantially increased from baseline to 1 month after PCV20 vaccination for all 20 serotypes. Overall, GMFRs ranged from 5.9 (serotype 14) to 49.8 (23F) for PCV13 serotypes and from 5.4 (11A) to 75.7 (12F) for the 7 additional PCV20 serotypes. Most local reactions and systemic events were mild or moderate in severity and transient. Overall, 2.3% of participants reported any AE through 1 month after vaccination. No related, immediate, severe, or serious AEs were reported. Consistent with previous trials, PCV20 elicited robust immune responses to all 20 serotypes following a single dose and was well tolerated with an acceptable safety profile in Indian adults ≥18 y of age. NCT05875727.

2026-12-31·Human Vaccines & Immunotherapeutics

Clinical effectiveness and impact of 13-valent pneumococcal conjugate vaccines in preventing invasive pneumococcal disease among children with risk conditions: A systematic literature review

Review

作者: Chapman, Ruth ; Hayford, Kyla ; Tort, Maria J. ; Huang, Liping ; Forbes, Carol ; Theilacker, Christian ; Pustulka, Iwona

Few studies have reported vaccine effectiveness (VE) and population-level impact of the 13-valent pneumococcal conjugate vaccination (PCV13) among children with immunocompromising or chronic medical conditions putting them at risk of developing pneumococcal disease. The objective of this systematic literature review (SLR) was to summarize the efficacy, effectiveness, and impact of PCV13 in the prevention of invasive pneumococcal disease (IPD) and all-cause pneumonia among children with risk conditions. Peer-reviewed studies published between January 2000 and July 2024 were identified in MEDLINE, Embase, CENTRAL, and CDSR. Of 3008 records identified, full texts of 189 studies (6.3%) were reviewed and 11 (0.4%) studies evaluating PCV13 alone or in combination with PCV7 were included. Vaccine effectiveness or impact of PCV13 was reported in children with sickle cell disease (SCD; n = 2), HIV (n = 4), post-transplant conditions (n = 1), cancer (n = 1), combined immunocompromising conditions (n = 1), combined chronic medical and immunocompromising conditions (n = 1), and congenital heart disease (n = 1). In children with immunocompromising conditions, VE against PCV13-type IPD ranged between 83.8% and 91%. Compared to the pre-PCV era, the introduction of PCV13 in pediatric immunization programs was associated with a relative reduction of IPD due to any serotype between 86% and 100% in children SCD and 55% to 80% in children with cancer. PCV impact, as measured by incidence rate reductions, among children with HIV varied by comparison period, age group and outcome and ranged from 9.1% to 81% for any IPD. These findings support PCV vaccination for children with risk conditions although evidence was limited and heterogeneous.

201

项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的新闻（医药）

2026-06-05

·腾讯网

豪掷261亿！礼来一天收购三家疫苗公司，打的什么算盘？

5月26日，礼来同时宣布收购三家疫苗企业，Curevo Inc（102.44亿元）、LimmaTech Biologics AG（53.27亿元）、Vaccine Company, Inc（105.85亿元），总金额逼近261亿元人民币。疫苗的“慢病账本”单看这3笔收购，Curevo的带状疱疹疫苗未来能挑战GSK的王牌Shingrix，LimmaTech的金葡菌疫苗应对了抗生素耐药，Vaccine Company的EBV疫苗填补了无疫苗空白。根据现有研究证实，带状疱疹会增加中风风险，接种带状疱疹疫苗与痴呆风险下降相关；金葡菌等耐药菌的反复感染，不仅直接危及生命，其带来的长期组织损伤与免疫消耗，正在被逐步证实与多种慢性病相关；而EB病毒也已被证实与多发性硬化症及多种恶性肿瘤密切相关。Curevo的带状疱疹疫苗在头对头II期试验中，免疫应答非劣效于Shingrix，同时将疲劳、畏寒、注射部位疼痛等副作用降低超过一半。Shingrix最大的痛点是不良反应导致接种率偏低、第二针犹豫。Curevo一旦提升覆盖率，从中风到痴呆的远期获益将成倍放大。表1：CRV-101的II期临床试验（NCT05304351）关键数据数据来源：Pharma ONE药物研发大数据平台-全球临床试验板块，中国医药工业信息中心整理EBV疫苗看似小众，一旦证实能降低多发性硬化症和鼻咽癌发病率，就会成为“预防癌症的疫苗2.0”。金葡菌疫苗若能成为外科手术标配，术后感染的致死风险将被大幅压缩，而美国每年仅院内感染就有数十亿美元的社会负担。所以，礼来的目标是用疫苗做慢病的上游拦截。三笔收购，一张预防网礼来目前的研发管线横跨四大领域：代谢疾病（GLP-1类药物为核心）、神经科学（阿尔茨海默病为重点）、肿瘤和免疫。其中，代谢领域的替尔泊肽在2025年已成为全球药王，口服GLP-1 Orforglipron也于今年获批上市，三靶点激动剂Retatrutide处于III期；神经科学方面，阿尔茨海默病药物donanemab（Kisunla）已全球上市。但这四大领域间此前缺乏一条纵向联结线索，患者在一个领域接受治疗，可能同时面临另一个领域疾病风险的隐性关联。此次疫苗收购刚好可以填补该缺口，纵向上打通“感染→慢病”上下游链条。疫苗业务在MNC的定位，通常是独立于核心治疗领域外的“传染病板块”。比如辉瑞有Prevnar，默沙东有Gardasil，GSK有Shingrix，但它们与各自的肿瘤、神经、代谢管线之间缺乏直接的协同逻辑。而礼来对于疫苗资产的选择，遵循了一条“感染→慢病”的链逻辑：● 神经科学/阿尔茨海默病（donanemab已上市） → 带状疱疹感染后痴呆风险增加，接种疫苗可降低风险约32%-50% → 收购 Curevo（带状疱疹疫苗）→ 预防感染，从源头降低痴呆和阿尔茨海默病的上游风险；● 神经科学/多发性硬化症 → EBV感染与MS存在32倍风险关联 → 收购 Vaccine Company（EBV疫苗）→ 预防EBV感染，理论上可阻断MS的病原驱动因素；● 肿瘤学（Jaypirca血液瘤等） → EBV与淋巴瘤、鼻咽癌等多种恶性肿瘤密切相关，全球每年约20万新发EBV相关恶性肿瘤 → 收购 Vaccine Company（EBV疫苗）→ 从病毒源头预防EBV驱动型肿瘤的发生；● 代谢/GLP-1（糖尿病患者、肥胖患者感染风险高） → 肥胖和糖尿病患者是金葡菌等高感染风险人群，且病程中感染将进一步加重代谢紊乱 → 收购 LimmaTech（金葡菌及耐药菌疫苗）→ 在代谢疾病高危人群中降低感染负担，减少治疗复杂性；● 免疫学（Taltz银屑病、Omvoh炎症性肠病等自身免疫疾病） → 自身免疫病患者感染风险升高且治疗难度更大 → 收购 LimmaTech + 平台化能力 → 为礼来庞大的免疫患者群体提供感染防控的前置手段。从这个视角看，礼来的“上游拦截”重新定义了疫苗竞争坐标，被收购企业的竞争对手不是其他疫苗企业，而是下游治疗领域占据主导地位的同类产品。七十年后，礼来再入疫苗局早在1955年，礼来就是全球首家大规模生产并销售索尔克脊髓灰质炎疫苗的企业。从青霉素的大规模生产，到脊髓灰质炎疫苗的全球首发，礼来曾是全球传染病防控的绝对主角。随后数十年间，公司重心逐步转移，淡出人类疫苗自主研发。去年10月，礼来聘请前FDA官员Peter Marks牵头疫苗业务，此举被外界视为礼来重返疫苗赛道、全面加强传染病业务的重要信号。而此时，美国疫苗行业正面临“不确定局势”，HHS终止了5亿美元的BARDA合同，BioNTech关停四家工厂裁撤1860人专注于肿瘤管线，多家疫苗巨头（辉瑞、GSK、赛诺菲、默沙东）的美国疫苗销售集体下滑。在部分制药企业收缩疫苗业务时，礼来选择逆势加码，押注“预防医学成为大制药核心”的范式转移。数据来源：公开信息，中国医药工业信息中心整理上游拦截的逻辑成立，不等于商业回报兑现。礼来的大赚之路，还横着临床验证、接种意愿和政策风向三道坎。261亿元是远见还是冒险，只有时间能给出答案。声明：*本文仅提供信息参考，不代表本平台观点。

2026-05-29

·Healthcare Digital

Pfizer Advances Next-Gen Paediatric Vaccine to Phase 3

Pfizer's paediatric vaccine reaches Phase 3 of trials. Credit: Pfizer Encouraging Phase 2 results show a robust immune response against serotype 3, prompting pivotal Phase 3 trials to protect up to 90% of paediatric patients Pfizer has announced the advancement of its pivotal paediatric pneumococcal vaccine programme following encouraging data from its Phase 2 clinical trial. The company has initiated its Phase 3 clinical trial for an investigational 25-valent pneumococcal conjugate vaccine candidate, designated PF-07872412 or 25vPnC, in infants. Alongside this milestone, Pfizer has unveiled plans to progress its adult vaccine strategy by moving straight to a fifth-generation 35-valent candidate. Strong immunogenicity shown in phase 2 results The decision to progress into a Phase 3 programme follows positive data from a Phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose series of the 25vPnC candidate in healthy infants. In this randomised trial, which began initial enrolment in July 2024, participants received either the 25vPnC candidate or the existing licensed standard-of-care vaccine, PREVNAR 20, at two, four, six and 12-15 months of age. Preliminary findings from the study were delivered during an oral presentation at the 14th meeting of the International Society of Pneumonia & Pneumococcal Diseases (ISPPD) in Copenhagen, Denmark. The results showed robust immune responses across all 25 included serotypes. Crucially, the investigational vaccine elicited an enhanced response against serotype 3, which continues to be a major cause of invasive pneumococcal disease and complicated pneumonia in young children. Data revealed that one month after the third dose, geometric mean titers for serotype 3 were 8.8-fold higher in infants given 25vPnC than in those who received PREVNAR 20, with scores of 4.22 versus 0.48 respectively. One month after the fourth dose, the gap widened further, with 25vPnC producing a serotype 3 immunogenicity response approximately 15-fold higher than PREVNAR 20, recording titers of 13.85 compared to 0.92. Broader disease coverage and safety The 25vPnC candidate builds upon the 20 serotypes already included in PREVNAR 20 by introducing five new serotypes: 15A, 23A, 23B, 24F and 35B. This addition expands protection to cover up to 90% of disease-causing serotypes in children under five years of age, representing an additional 25% coverage of invasive pneumococcal disease cases compared to PCV20. In terms of safety, the investigational vaccine was well-tolerated with no safety concerns identified during the Phase 2 study. The safety and tolerability profile remained consistent with currently approved pneumococcal vaccines, with the most common local reactions being typical injection site symptoms such as redness, swelling or pain. Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer “For more than 25 years, our vaccines have helped protect children from pneumococcal disease, yet a significant disease burden remains,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. “These Phase 2 results reinforce our confidence in a next-generation vaccine designed to expand protection across serotypes while improving responses to key residual disease drivers such as serotype 3. We are advancing our Phase 3 programme with the goal of delivering broader and more durable protection for children.” Launching the paediatric phase 3 programme Based on the robust immune responses observed across the Phase 2 programme and following collaborative discussions with regulatory authorities, Pfizer officially initiated its pivotal paediatric Phase 3 programme in May 2026. The company remains confident that the candidate will meet the necessary non-inferiority thresholds required in this definitive stage of testing. The upcoming Phase 3 studies will assess the safety, tolerability and immunogenicity of 25vPnC in up to 2,400 healthy children. Participants will be allocated to receive the exact same vaccine for all four scheduled doses, comparing 25vPnC directly to the licensed 20-valent standard-of-care vaccine at two, four, six and 12 to 15 months of age. Evolution of the adult vaccine strategy Simultaneously, Pfizer has chosen a direct pathway to maintain its long-term market leadership within the adult sector. The biopharmaceutical firm has decided to bypass intermediate clinical steps and move straight to a fifth-generation adult vaccine candidate that covers 35 serotypes. This adult candidate will leverage Pfizer's proprietary next-generation technology to enhance immunogenicity for critical strains, including serotype 3, while expanding overall serotype coverage. Pending alignment with regulatory authorities, this 35-valent adult vaccine candidate is projected to enter clinical development by the end of 2026. Company portals Pfizer Executives Annaliesa Anderson, Ph.D. Senior Vice President and Chief Vaccines Officer

临床2期疫苗临床3期临床结果

2026-05-27

·医药地理

261亿！礼来买走3家潜力股

5月26日，礼来同时宣布收购三家疫苗企业，Curevo Inc（102.44亿元）、LimmaTech Biologics AG（53.27亿元）、Vaccine Company, Inc（105.85亿元），总金额逼近261亿元人民币。 01 疫苗的“慢病账本” 单看这3笔收购，Curevo的带状疱疹疫苗未来能挑战GSK的王牌Shingrix，LimmaTech的金葡菌疫苗应对了抗生素耐药，Vaccine Company的EBV疫苗填补了无疫苗空白。根据现有研究证实，带状疱疹会增加中风风险，接种带状疱疹疫苗与痴呆风险下降相关；金葡菌等耐药菌的反复感染，不仅直接危及生命，其带来的长期组织损伤与免疫消耗，正在被逐步证实与多种慢性病相关；而EB病毒也已被证实与多发性硬化症及多种恶性肿瘤密切相关。 Curevo的带状疱疹疫苗在头对头II期试验中，免疫应答非劣效于Shingrix，同时将疲劳、畏寒、注射部位疼痛等副作用降低超过一半。Shingrix最大的痛点是不良反应导致接种率偏低、第二针犹豫。Curevo一旦提升覆盖率，从中风到痴呆的远期获益将成倍放大。表1：CRV-101的II期临床试验（NCT05304351）关键数据数据来源：Pharma ONE药物研发大数据平台-全球临床试验板块，中国医药工业信息中心整理点击“阅读原文”获取更多数据 EBV疫苗看似小众，一旦证实能降低多发性硬化症和鼻咽癌发病率，就会成为“预防癌症的疫苗2.0”。金葡菌疫苗若能成为外科手术标配，术后感染的致死风险将被大幅压缩，而美国每年仅院内感染就有数十亿美元的社会负担。所以，礼来的目标是用疫苗做慢病的上游拦截。 02 三笔收购，一张预防网礼来目前的研发管线横跨四大领域：代谢疾病（GLP-1类药物为核心）、神经科学（阿尔茨海默病为重点）、肿瘤和免疫。其中，代谢领域的替尔泊肽在2025年已成为全球药王，口服GLP-1 Orforglipron也于今年获批上市，三靶点激动剂Retatrutide处于III期；神经科学方面，阿尔茨海默病药物donanemab（Kisunla）已全球上市。但这四大领域间此前缺乏一条纵向联结线索，患者在一个领域接受治疗，可能同时面临另一个领域疾病风险的隐性关联。此次疫苗收购刚好可以填补该缺口，纵向上打通“感染→慢病”上下游链条。疫苗业务在MNC的定位，通常是独立于核心治疗领域外的“传染病板块”。比如辉瑞有Prevnar，默沙东有Gardasil，GSK有Shingrix，但它们与各自的肿瘤、神经、代谢管线之间缺乏直接的协同逻辑。而礼来对于疫苗资产的选择，遵循了一条“感染→慢病”的链逻辑： ●神经科学/阿尔茨海默病（donanemab已上市） → 带状疱疹感染后痴呆风险增加，接种疫苗可降低风险约32%-50% → 收购 Curevo（带状疱疹疫苗）→ 预防感染，从源头降低痴呆和阿尔茨海默病的上游风险； ●神经科学/多发性硬化症 → EBV感染与MS存在32倍风险关联 → 收购 Vaccine Company（EBV疫苗）→ 预防EBV感染，理论上可阻断MS的病原驱动因素； ●肿瘤学（Jaypirca血液瘤等） → EBV与淋巴瘤、鼻咽癌等多种恶性肿瘤密切相关，全球每年约20万新发EBV相关恶性肿瘤 → 收购 Vaccine Company（EBV疫苗）→ 从病毒源头预防EBV驱动型肿瘤的发生； ●代谢/GLP-1（糖尿病患者、肥胖患者感染风险高） → 肥胖和糖尿病患者是金葡菌等高感染风险人群，且病程中感染将进一步加重代谢紊乱 → 收购 LimmaTech（金葡菌及耐药菌疫苗）→ 在代谢疾病高危人群中降低感染负担，减少治疗复杂性； ●免疫学（Taltz银屑病、Omvoh炎症性肠病等自身免疫疾病） → 自身免疫病患者感染风险升高且治疗难度更大 → 收购 LimmaTech + 平台化能力 → 为礼来庞大的免疫患者群体提供感染防控的前置手段。从这个视角看，礼来的“上游拦截”重新定义了疫苗竞争坐标，被收购企业的竞争对手不是其他疫苗企业，而是下游治疗领域占据主导地位的同类产品。 03 七十年后，礼来再入疫苗局早在1955年，礼来就是全球首家大规模生产并销售索尔克脊髓灰质炎疫苗的企业。从青霉素的大规模生产，到脊髓灰质炎疫苗的全球首发，礼来曾是全球传染病防控的绝对主角。随后数十年间，公司重心逐步转移，淡出人类疫苗自主研发。去年10月，礼来聘请前FDA官员Peter Marks牵头疫苗业务，此举被外界视为礼来重返疫苗赛道、全面加强传染病业务的重要信号。而此时，美国疫苗行业正面临“不确定局势”，HHS终止了5亿美元的BARDA合同，BioNTech关停四家工厂裁撤1860人专注于肿瘤管线，多家疫苗巨头（辉瑞、GSK、赛诺菲、默沙东）的美国疫苗销售集体下滑。在部分制药企业收缩疫苗业务时，礼来选择逆势加码，押注“预防医学成为大制药核心”的范式转移。数据来源：公开信息，中国医药工业信息中心整理上游拦截的逻辑成立，不等于商业回报兑现。礼来的大赚之路，还横着临床验证、接种意愿和政策风向三道坎。261亿元是远见还是冒险，只有时间能给出答案。互动投票 END 👇欢迎扫码入群 ①权威报告获取 ②医药行业情报 ③专属交流平台戳“阅读原文”试用数据库

疫苗并购临床3期临床2期微生物疗法

100 项与肺炎球菌7价结合疫苗(Pfizer Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	肺炎球菌7价结合疫苗(Pfizer Inc.)	J07AL02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性中耳炎	欧盟	Pfizer Ltd.	2001-02-02
急性中耳炎	冰岛	Pfizer Ltd.	2001-02-02
急性中耳炎	列支敦士登	Pfizer Ltd.	2001-02-02
急性中耳炎	挪威	Pfizer Ltd.	2001-02-02
菌血症	欧盟	Pfizer Ltd.	2001-02-02
菌血症	冰岛	Pfizer Ltd.	2001-02-02
菌血症	列支敦士登	Pfizer Ltd.	2001-02-02
菌血症	挪威	Pfizer Ltd.	2001-02-02
脑膜炎	欧盟	Pfizer Ltd.	2001-02-02
脑膜炎	冰岛	Pfizer Ltd.	2001-02-02
脑膜炎	列支敦士登	Pfizer Ltd.	2001-02-02
脑膜炎	挪威	Pfizer Ltd.	2001-02-02
肺炎球菌感染	欧盟	Pfizer Ltd.	2001-02-02
肺炎球菌感染	冰岛	Pfizer Ltd.	2001-02-02
肺炎球菌感染	列支敦士登	Pfizer Ltd.	2001-02-02
肺炎球菌感染	挪威	Pfizer Ltd.	2001-02-02
肺炎	欧盟	Pfizer Ltd.	2001-02-02
肺炎	冰岛	Pfizer Ltd.	2001-02-02
肺炎	列支敦士登	Pfizer Ltd.	2001-02-02
肺炎	挪威	Pfizer Ltd.	2001-02-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌性脑膜炎	临床3期	德国	Pfizer Inc.	2008-03-01
肺炎球菌性肺炎	临床2期	约旦	Wyeth AB	2009-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00622843 (CTgov)	临床3期	肺炎球菌性肺炎 \| HIV感染	275	pneumococcal conjugate vaccine (Group 1)	鑰鬱膚積鹹網夢齋簾衊(鹹鬱蓋簾夢願築窪衊簾) = 夢淵鏇構願製衊憲繭衊築獵構積餘膚顧膚膚積 (範觸網夢鏇窪觸鹽構壓, 22.29) 更多	-	2025-06-08
				pneumococcal polysaccharide vaccine (Group 2)	鑰鬱膚積鹹網夢齋簾衊(鹹鬱蓋簾夢願築窪衊簾) = 憲範繭壓範窪廠簾壓範築獵構積餘膚顧膚膚積 (範觸網夢鏇窪觸鹽構壓, 28.08) 更多
NCT00153543 (CTgov)	临床1期	肺炎球菌感染	86	PCV7 (PPV23)	願糧齋鏇積夢積醖膚壓(鹹製鹽夢糧網遞艱簾繭) = 築襯窪壓夢鬱鬱鑰鏇範觸鏇製鹹簾鏇廠觸繭構 (鬱積壓網鏇鹹鬱顧醖艱, 積鹹蓋獵襯壓製簾鹽夢 ~ 積窪齋憲壓憲壓蓋齋醖) 更多	-	2024-10-01
				PCV7 (PCV7 + PPV23, 2 Months)	願糧齋鏇積夢積醖膚壓(鹹製鹽夢糧網遞艱簾繭) = 夢顧壓製膚網鏇築鹽鹽觸鏇製鹹簾鏇廠觸繭構 (鬱積壓網鏇鹹鬱顧醖艱, 糧觸觸選蓋鬱選繭壓簾 ~ 獵鏇鹹憲襯鏇糧願艱願) 更多
NCT00566098 (CTgov)	临床1/2期	多发性骨髓瘤	26	Melphalan+MILs+PCV13	窪鏇壓觸襯築構齋遞壓(艱繭夢觸廠糧積選獵觸) = 繭糧獵遞窪獵餘蓋選鹽膚窪築衊齋衊鬱選鏇衊 (遞繭醖鏇餘糧遞願遞製, 顧鑰壓蓋鏇衊壓遞繭遞 ~ 夢積衊鏇網構膚壓顧窪) 更多	-	2018-12-19
NCT01307449 (CTgov)	N/A	肺炎球菌感染	88	PNEUMOVAX (Older Group (60-89) on PNEUMOVAX)	鹹獵遞壓製遞鹽蓋遞範 = 構糧構壓鑰範顧鑰餘襯鏇襯餘簾齋構遞窪夢積 (顧壓製構襯簾選繭餘鹽, 築壓鹹窪範網廠簾蓋夢 ~ 顧製構窪鏇遞艱範願積) 更多	-	2018-10-02
				PREVNAR (Older Group (60-89) on PREVNAR)	鹹獵遞壓製遞鹽蓋遞範 = 鹹糧顧廠襯窪鹹蓋夢顧鏇襯餘簾齋構遞窪夢積 (顧壓製構襯簾選繭餘鹽, 蓋獵齋齋衊襯鏇獵醖夢 ~ 夢製夢網觸構醖夢遞淵) 更多
NCT00569309 (CTgov)	N/A	多发性骨髓瘤 \| 小肠癌	30	laboratory correlative studies+Streptococcus pneumoniae	襯廠醖簾夢鑰衊衊夢網 = 艱構糧糧鹹衊膚積構醖膚夢齋襯醖獵製襯範網 (衊壓淵鹽齋鏇築鑰窪壓, 鹽廠窪夢廠鹽鏇襯獵壓 ~ 願艱遞衊齋繭觸鹽齋鏇) 更多	-	2018-03-12
NCT00381615 (CTgov)	临床2期	-	147	rMenB+DTaP-Hib-IPV+MenC-CRM+MMR+MenC-Hib+PC7 (rMenB)	蓋願窪醖選窪鑰選齋範 = 衊蓋範積觸衊繭膚築餘鬱衊糧鏇積膚餘艱廠遞 (願範顧鹽鏇憲壓衊齋簾, 獵鏇網構獵糧蓋鑰顧構 ~ 繭觸蓋艱鹽簾鬱襯積簾) 更多	-	2015-10-09
				DTaP-Hib-IPV+rMenB+OMV+MenC-CRM+MMR+MenC-Hib+PC7 (rMenB+OMV)	蓋願窪醖選窪鑰選齋範 = 鑰糧膚窪鬱顧鏇繭壓鏇鬱衊糧鏇積膚餘艱廠遞 (願範顧鹽鏇憲壓衊齋簾, 廠夢鑰鬱壓壓觸憲網淵 ~ 築齋觸鹽廠鑰廠鬱壓壓) 更多
NCT00457977 (PNEUMO, CTgov)	临床3期	慢性阻塞性肺疾病	181	Pneumovax (Pneumovax (PPSV23))	憲壓窪選鹽繭膚蓋淵壓(選簾範窪醖齋糧齋鬱蓋) = 製齋齋襯積鹽獵構窪選醖顧憲鏇鏇憲餘簾廠簾 (獵選範憲窪衊淵醖淵夢, 顧鑰觸憲夢醖淵積願衊 ~ 廠壓襯蓋鹽願範艱網餘) 更多	-	2015-05-12
				PCV7 (Prevnar (PCV7))	憲壓窪選鹽繭膚蓋淵壓(選簾範窪醖齋糧齋鬱蓋) = 膚簾獵鹹窪鹽繭遞膚遞醖顧憲鏇鏇憲餘簾廠簾 (獵選範憲窪衊淵醖淵夢, 顧壓網構鏇廠衊築鑰願 ~ 餘膚衊壓製襯鏇構蓋憲) 更多
NCT00667602 (CTgov)	临床3期	流行性脑脊髓膜炎	662	MenACWY-CRM197 (1dose) (MenACWY-CRM197 (1dose) + Concomitant Vaccines)	積齋積淵壓選願築積壓 = 鹽獵構觸鹽遞獵鑰範膚壓蓋憲願鹽範鑰衊選簾 (壓鹹襯壓糧鹹繭蓋選築, 範壓繭糧醖築繭構構觸 ~ 醖糧糧選網觸鬱鑰淵範) 更多	-	2013-11-07
				MenC (1dose) (MenC (1dose) + Concomitant Vaccines)	積齋積淵壓選願築積壓 = 鏇窪艱獵構醖製築觸夢壓蓋憲願鹽範鑰衊選簾 (壓鹹襯壓糧鹹繭蓋選築, 顧淵簾願鹽顧築簾鬱襯 ~ 淵積範簾糧夢膚夢憲觸) 更多
NCT01250756 (CTgov)	临床4期	白喉 \| 破伤风	321	diphtheria, tetanus, and acellular pertussis vaccine (DTaP)+7-valent pneumococcal conjugate vaccine (7vPnC) (7vPnC + DTaP)	淵廠鑰鬱蓋積簾衊願簾 = 獵簾淵淵鹽範鬱壓艱淵衊遞淵遞衊襯鑰鬱餘艱 (廠製構膚餘網壓繭選遞, 蓋觸選鹽夢廠窪鏇蓋醖 ~ 糧觸醖廠襯醖膚艱觸餘) 更多	-	2013-02-26
				DTaP (DTaP (Catch-up 7vPnC))	淵廠鑰鬱蓋積簾衊願簾 = 蓋醖窪製淵衊壓廠築衊衊遞淵遞衊襯鑰鬱餘艱 (廠製構膚餘網壓繭選遞, 遞顧構網範製齋齋鑰膚 ~ 選憲製遞鏇壓鏇襯膚廠) 更多
NCT00189020 (Pubmed \| PLoS One)	临床3期	金黄色葡萄球菌感染	1,005	seven-valent pneumococcal conjugate vaccine (PCV7 at 2, 4, and 11 months)	選願夢選獵醖齋築壓鏇(鹽艱鹹蓋窪範獵糧襯鑰) = 繭製簾糧齋範憲餘糧淵餘齋遞鏇鑰廠憲簾網鹽 (艱網網積膚願鏇襯夢製 )	-	2011-01-01
				seven-valent pneumococcal conjugate vaccine (No PCV7 (controls))	選願夢選獵醖齋築壓鏇(鹽艱鹹蓋窪範獵糧襯鑰) = 獵積艱膚積選鏇淵襯繭餘齋遞鏇鑰廠憲簾網鹽 (艱網網積膚願鏇襯夢製 )